Skip to main content
. 2023 Jun 15;13:1185198. doi: 10.3389/fonc.2023.1185198

Figure 2.

Figure 2

Clinical efficacy analysis with waterfall plots of patients evaluable by RECIST (n=32). NA, not applicable; AdCC, Adenoid cystic carcinoma; SDC, Salivary duct carcinoma; ANOS, Adenocarcinoma, NOS; CEPA, Carcinoma ex pleomorphic adenoma, PDC, Poorly differentiated carcinoma; MEC, Mucoepidermoid carcinoma.